NasdaqCM - Nasdaq Real Time Price • USD
Enveric Biosciences, Inc. (ENVB)
As of 1:30 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 1 |
| Avg. Estimate | -0.77 | -0.53 | -2.66 | -1.41 |
| Low Estimate | -0.94 | -0.55 | -3.25 | -1.41 |
| High Estimate | -0.61 | -0.52 | -2.08 | -1.41 |
| Year Ago EPS | -2.47 | -3.04 | -8.09 | -2.66 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 9/30/2022 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -4 | -0.65 | -2.09 | -1.54 |
| EPS Actual | -2.47 | -3.04 | -1.3 | -1.47 |
| Difference | 1.53 | -2.39 | 0.79 | 0.07 |
| Surprise % | 38.30% | -367.70% | 37.80% | 4.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.77 | -0.53 | -2.66 | -1.41 |
| 7 Days Ago | -0.77 | -0.53 | -2.66 | -1.41 |
| 30 Days Ago | -1.28 | -0.79 | -2.65 | -0.63 |
| 60 Days Ago | -1.28 | -0.79 | -2.65 | -1.54 |
| 90 Days Ago | -1.28 | -0.79 | -3.44 | -2.45 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 1 | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ENVB | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 68.80% | -- | -- | 0.80% |
| Next Qtr. | 82.60% | -- | -- | 9.60% |
| Current Year | 67.10% | -- | -- | 4.50% |
| Next Year | 47.00% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Initiated | HC Wainwright & Co.: Buy | 1/30/2024 |
Related Tickers
ENTX Entera Bio Ltd.
1.9794
-11.63%
YMAB Y-mAbs Therapeutics, Inc.
15.07
+0.47%
XLO Xilio Therapeutics, Inc.
1.1936
-6.73%
PHIO Phio Pharmaceuticals Corp.
0.6500
+2.36%
TENX Tenax Therapeutics, Inc.
3.6250
-1.73%
REVB Revelation Biosciences, Inc.
2.1800
-1.36%
KTRA Kintara Therapeutics, Inc.
0.1237
+16.04%
TCBP TC Biopharm (Holdings) Plc
1.4660
+3.24%
OCEA Ocean Biomedical, Inc.
1.8000
-3.98%
ADTX Aditxt, Inc.
2.3500
-2.49%